Abbott announces a new cardiovascular device manufacturing plant in Georgia for 2028, its second major U.S. investment in 2025. Follows a $500M transfusion diagnostics expansion into a $1B molecular testing market.
Second Major 2025 Investment Strengthens Domestic Production of Medical Devices and Diagnostics
Abbott Park, IL / Georgia, USA – Global healthcare leader Abbott has announced plans to construct a new state-of-the-art cardiovascular device manufacturing facility in Georgia slated for completion in 2028. This strategic investment, the company’s second major U.S. manufacturing announcement this year is driven by robust double-digit sales growth in its Electrophysiology, Heart Failure, and Structural Heart businesses.
The new facility underscores Abbott’s long-term commitment to onshoring critical healthcare manufacturing and reinforces the resilience of its U.S.-based supply chain.
A One-Two Punch of U.S. Investment in 2025
The Georgia cardiovascular plant is the latest in a series of substantial investments by Abbott to expand its American manufacturing footprint:
- April 2025: Abbott announced a $500 million investment to expand its transfusion diagnostics business, which screens over 50% of the global blood and plasma supply. This project is set to create 300 new American jobs.
- New Georgia Facility: The new cardiovascular device plant represents a further deepening of Abbott’s U.S. operations, details of which are still emerging.
These moves are part of a massive five-year investment strategy that has seen Abbott pour over $15 billion into U.S. operations, including manufacturing, equipment, and R&D. The company maintains its world headquarters in Illinois and operates 35 manufacturing sites across 15 states and 43 R&D sites in 13 states, representing its largest global presence.
Entering a $1 Billion Molecular Diagnostics Market
A key aspect of the previously announced $500 million transfusion diagnostics expansion is Abbott’s entry into the molecular nucleic acid testing market, estimated to be a $1 billion opportunity.
The expansion will introduce the Alinity n system, a compact, next-generation instrument designed to perform molecular testing capable of detecting DNA and RNA for multiple pathogens like HIV and hepatitis. This will complement Abbott’s existing Alinity s system, which runs serology tests, creating a comprehensive screening suite to ensure the safety of blood and plasma transfusions.
Elizabeth Balthrop, Vice President of Transfusion Medicine at Abbott, highlighted the customer-centric design: “We’ve visited key organizations globally to understand their pain points… The feedback has been encouraging as they think about how to manage their blood and plasma supply.”
Driving Growth Through Innovation and Strategic Onshoring
These investments are strategically timed. The new cardiovascular facility capitalizes on strong market demand, while the diagnostics expansion opens a new, high-growth market segment. Together, they:
- Strengthen U.S. Supply Chains: Reducing dependency on foreign manufacturing for critical medical devices and diagnostic tools.
- Create High-Skilled Jobs: Adding hundreds of new positions in manufacturing, engineering, and R&D.
- Accelerate Innovation: Keeping research, development, and production closely linked to speed up the delivery of next-generation healthcare solutions.
By continuing to invest heavily stateside, Abbott is not just future-proofing its own business; it is also playing a vital role in bolstering the national infrastructure for medical innovation and production security.
